The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Colorectal cancer is typically diagnosed after age 50, but in recent years the disease has been increasingly found in younger people and disproportionately affecting racial and ethnic minorities.

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Lynch syndrome, a genetic condition caused by germline mutations in DNA mismatch repair genes, significantly increases cancer ...

Genetic testing is recommended for those with personal and family histories of several types of cancer — including pancreatic ...

Safety: Aspirin was well-tolerated, with no major safety concerns reported. The ASCOLT trial showed that aspirin did not ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

The following is a summary of “Introducing Neoadjuvant Immunotherapy for Colorectal Cancer: Advancing the Frontier,” ...

The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...

Women are now being diagnosed with cancer more often than men in certain age groups, according to a new report from the ...